### Xylometazoline

**Section:** 28. Ear, nose and throat medicines [c]

**Essential medicine status**

**ATC codes:**
- R01AA07
- EMLc

**Indication**
- Nasal congestion

**ICD11 code:**
- MF11.7

**INN**
- Xylometazoline

**Medicine type**
- Chemical agent

**List type**
- Core

**Formulations**
- Local > Nasal > Spray: 0.05% w/v equivalent to 0.5 mg per mL (EMLc)

**EML status history**
- First added in 2009 (TRS 958)
- Changed in 2021

**Sex**
- All

**Age**
- Children (1 month - 12 years)

**Age restriction**
- Not in children less than 3 months

**Therapeutic alternatives**
- Medicines within the same pharmacological class can be used

**Therapeutic alternatives limitations for EMLc**
- Therapeutic alternatives to be reviewed (2023)

**Patent information**
- Patents have expired in most jurisdictions
  - Read more about patents.

**Wikipedia**
- [Xylometazoline](https://en.wikipedia.org/wiki/Xylometazoline)

**DrugBank**
- [Xylometazoline](https://www.drugbank.ca/drugs/DB00392)

---

**Summary of evidence and Expert Committee recommendations**

Following the review of square box listings on the EML and EMLc, the Expert Committee recommended the therapeutic alternatives for xylometazoline nasal spray be reviewed.